Contract

Exhibit 10.2

 

This Employment Agreement is entered into as of August 1, 2025 (the “Agreement”) by and between Tenon Medical, Inc. (the “Company”), and ▇▇▇▇ ▇▇▇▇▇▇ (“Executive”).

 

RECITALS

 

WHEREAS, Executive has executed the Confidential Information, Invention Assignment and Arbitration Agreement on or before the Effective Date in favor of the Company (the “Confidential Information Agreement”); and

 

WHEREAS, Executive and Company wish to enter into this Agreement to memorialize the other terms of Executive’s employment with the Company as of the Effective Date.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the mutual promises made herein, the Company and Executive hereby agree as follows:

 

1. Duties and Scope of Employment.

 

(a) Positions and Duties. Executive will serve as the Chief Commercial Officer of the Company effective as of August 1, 2025 (the “Effective Date”). Executive will render such business and professional services in the performance of his duties, consistent with Executive’s position within the Company, as will reasonably be assigned to him by the Board. The Executive shall report to the Company’s Chief Executive Officer. The period of Executive’s employment under this Agreement is referred to herein as the “Employment Term.”

 

(b) Obligations. During the Employment Term, Executive will perform his duties faithfully consistent with industry standards and will devote his full business efforts and time to the Company during normal business hours. For the duration of the Employment Term, Executive agrees not to actively engage in any other employment, occupation or consulting activity for any direct or indirect remuneration, other than those which he is currently engaged, without the prior approval of the Board.

 

2. At-Will Employment. The parties agree that Executive’s employment with the Company will be “at-will” employment and may be terminated at any time with or without cause or notice. Executive understands and agrees that neither his job performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of his employment with the Company. However, as described in this Agreement, Executive may be entitled to severance benefits depending on the circumstances of Executive’s termination of employment with the Company.

 

 

3. Compensation.

 

(a) Base Salary. During the Employment Term, the Company will pay Executive an initial annual salary of $290,000 as compensation for his services (the “Base Salary”). The Base Salary will be paid periodically in accordance with the Company’s normal payroll practices and be subject to the usual, required withholding. Executive’s salary will be subject to review and adjustments will be made based upon the Company’s normal performance review practices.

 

(b) Commission Opportunity. In addition, Executive shall receive a monthly commission (the “Commissions”), payable within 45 days after the end of each applicable month, for sales of all products sold by the Company in such month above $250,000 (the “Monthly Threshold”), as follows: (i) during the one-year period following the Effective Date, the commission shall equal 5% of the Net Revenues in excess of the Monthly Threshold received by the Company during such month from the sale of its products, and (ii) during the one-year period following the first anniversary of Effective Date and ending on the second anniversary of the Effective Date, the commission shall equal 4% of the Net Revenues herein after defined in excess of the Monthly Threshold received by the Company during such month from the sale of its products; and (iii) during the three-year period following the second anniversary of Effective Date and ending on the fifth anniversary of the Effective Date, the commission shall equal 3% of the Net Revenues in excess of the Monthly Threshold received by the Company during such month from the sale of its products. As used herein, “Net Revenues” shall be equal to all product sales revenues, less chargebacks (refunds) credited to customers, returns, rebates and discounts awarded on or after the date of sale (and not already reflected in the initial calculated sales revenues. For clarification, references to the aggregate sales of the products shall include any sales by the Company or any subsidiary or other affiliate of the Company, as well as the Company’s successors and assigns. The Company will provide Executive with monthly reports as to the Company’s gross revenues, and at the request of Executive, such additional information as requested by Executive supporting the Company’s calculation of the gross revenues.

 

 

(c) Restricted Stock Award. The grant of a restricted stock award (the “Award”) of 138,114 shares (the “Original Restricted Stock”) of the Company’s common stock, $0.001 par value (the “Common Stock”), pursuant to the Company’s 2022 Equity Incentive Plan (as amended or as it may be amended, the “Plan”), which Restricted Stock will be issued promptly following shareholder approval to increase the number of shares reserved for issuance under the Plan; it being agreed and understood that the Original Restricted Stock shall be subject to vesting as set forth on Schedule A. It is hereby recognized that the Original Restricted Stock is equal to 1.75% of the Company’s issued and outstanding Common Stock as of the date of this Agreement. Commencing on the date of this Agreement until the earlier of (i) the termination of Executive’s employment or (ii) the fifth anniversary of this Agreement, if at any time any of the issued and outstanding Warrants of the Company as of the date hereof (the “Closing Date Warrants”) are exercised, or any of the issued and outstanding shares of Preferred Stock of the Company as of the date hereof (the “Closing Date Preferred Shares”) convert into shares of Common Stock, then the Company will issue to Executive additional shares of Common Stock (“Additional Restricted Stock”) equal to 1.75% of the shares of Common Stock issued by the Company as a result of the exercise of any Closing Date Warrants and/or the conversion of any Closing Date Preferred Shares. The Original Restricted Stock together with any Additional Restricted Stock, if applicable, is hereinafter referred to the “Restricted Stock”. The Company shall use commercially reasonable efforts to increase the number of shares reserved for issuance under the Plan in amounts sufficient enough to make the Restricted Stock Award to Executive as set forth in this Agreement. In the event that the Company is unable to issue the Restricted Stock under the Plan or otherwise prior to any Vesting Date, then promptly following such Vesting Date(s), the Company shall make a cash payment to Executive in an amount equal to the Assigned Share Value of such shares of Restricted Stock to vest on the Vesting Date. The “Assigned Share Value” shall be equal to the 10-day volume-weighted average per share price (“VWAP”) of the Company’s Common Stock ending on such applicable Vesting Date. The grant of the Restricted Stock is made in consideration of the services to be rendered by the Executive to the Company hereunder. Except as provided herein, if the Executive remains in continuous service with the Company through the applicable vesting date set forth in Schedule A, the Restricted Stock shall vest as set forth in such Schedule A. The Executive shall be the record owner of the Restricted Stock until the Executive sells or otherwise disposes such Restricted Stock or until such portion of unvested Restricted Stock is forfeited as a result of Executive not being employed at the applicable vesting date as set forth on Schedule A, and as a result, Executive shall be entitled to all of the rights of a shareholder of the Company including, without limitation, the right to vote such shares and receive all dividends or other distributions paid with respect to such shares until such time as the Restricted Stock is sold, disposed or forfeited. The Restricted Stock shall be subject to all trading and other policies of the Company including the Company’s ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ policy. Upon the closing of a Change in Control, subject to Executive’s continued employment through such date, Executive shall receive accelerated vesting of the Restricted Stock as to 100% of the then unvested and outstanding portion of the Restricted Stock.

 

 

4. Employee Benefits. During the Employment Term, Executive will be entitled to participate in the employee benefit plans currently and hereafter maintained by the Company of general applicability to other senior executives of the Company. The Company reserves the right to cancel or change the benefit plans and programs it offers to its employees at any time.

 

5. Paid Time Off. Executive will be entitled to 4 weeks of paid time off in accordance with the Company’s paid time off policy, with the timing and duration of specific vacations mutually and reasonably agreed to by Executive and the Chief Executive Officer. Executive will also participate in paid company holidays in accordance with the Company’s approved holiday schedule.

 

6. Expenses. The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in the furtherance of or in connection with the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policy as in effect from time to time.

 

7. Severance.

 

(a) Termination for other than Cause, Death or Disability or Resignation for Good Reason. If (i) the Company terminates Executive’s employment with the Company other than for Cause, death or disability, or (ii) Executive resigns from his employment with the Company for Good Reason, then, subject to Section 8, Executive will be entitled to: (A) receive continuing payments of severance pay at a rate equal to an annual salary of $290,000.00 or his Base Salary rate, as then in effect (or, in the event of Resignation for Good Reason pursuant to the event described in Section 10(d)(ii) hereof, a rate equal to an annual salary of $290,000.00 or his Base Salary rate, as in effect immediately prior to such event, whichever is greater), for twelve (12) months from the date of such termination in accordance with the Company’s normal payroll policies; (B) receive continuing payment of Commissions for the remainder of the five-year commission pay-out term set forth in Section 3(b) equal to 100% of the Commissions that would have been payable as set forth in Section 3(b) above; (C) Executive shall receive accelerated vesting of that number of shares of Restricted Stock that would become vested on the next Time Vesting Date and the next Earnout Vesting Date after the date of Termination; and (D) if Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) for Executive and Executive’s eligible dependents within the time period prescribed pursuant to COBRA, the Company will reimburse Executive for the COBRA premiums for such coverage (at the coverage levels in effect immediately prior to Executive’s termination) until the earlier of (1) a period of twelve (12) months from the last date of employment of the Executive with the Company, or (2) the date upon which Executive and/or Executive’s eligible dependents becomes covered under similar plans. COBRA reimbursements will be made by the Company to Executive consistent with the Company’s normal expense reimbursement policy. However, if the Company determines in its sole discretion that it cannot provide the COBRA benefits without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company will in lieu thereof provide to Executive a taxable monthly payment in an amount equal to the monthly COBRA premium that Executive would be required to pay to continue his or her group health coverage in effect on the date of his or her termination of employment (which amount will be after taxes and based on the premium for the first month of COBRA coverage), which payments will be made regardless of whether Executive elects COBRA continuation coverage. Notwithstanding anything to the contrary under this Agreement, if at any time the Company cannot provide the payments contemplated by the preceding sentence without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), Executive will not receive such payment or any further reimbursements for COBRA premiums.

 

 

(b) Termination for Cause, Death or Disability; Resignation without Good Reason. If Executive’s employment with the Company terminates voluntarily by Executive (except upon resignation for Good Reason), for Cause by the Company or due to Executive’s death or disability, then (i) all vesting will terminate immediately with respect to Executive’s outstanding Restricted Stock awards, (ii) all payments of compensation by the Company to Executive hereunder including, without limitation any Commissions, will terminate immediately (except as to amounts already earned), and (iii) Executive will only be eligible for severance benefits in accordance with the Company’s established policies, if any, as then in effect. Notwithstanding the foregoing, in the event of a termination for Cause other than pursuant to either clause (ii) or (v) of such definition, then the Company shall also pay the Executive as severance continuing payment of Commissions for the remainder of the five-year commission pay-out term set forth in Section 3(b) equal to 50% of the Commissions that would have been payable as set forth in Section 3(b) above.

 

8. Conditions to Receipt of Severance; No Duty to Mitigate.

 

(a) Separation Agreement and Release of Claims. The receipt of any severance pursuant to Section 7 will be subject to Executive signing and not revoking a separation agreement and release of claims in a form reasonably satisfactory to the Company and provided that such separation agreement and release of claims becomes effective and irrevocable no later than sixty (60) days following the termination date (such deadline, the “Release Deadline”). If the release of claims does not become effective by the Release Deadline, Executive will forfeit any rights to severance or benefits under this Agreement. In no event will severance payments or benefits be paid or provided until the release of claims becomes effective and irrevocable. Except as required by Section 8(c), any installment payments that would have been made to Executive during the sixty (60) day period immediately following his separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60th) day following Executive’s separation from service and the remaining payments will be made as provided in the Agreement.

 

(b) No Violations. The receipt of any severance benefits payable hereunder will be subject to Executive not violating the provisions of this Agreement applicable to Executive following any termination and the terms of the Confidential Information Agreement. In the event Executive breaches the provisions of this Agreement or the Confidential Information Agreement applicable to Executive following their termination, all continuing payments and benefits to which Executive may otherwise be entitled hereunder will immediately cease.

 

(c) Section 409A.

 

(i) Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to Executive, if any, pursuant to this Agreement, when considered together with any other severance payments or separation benefits that are considered deferred compensation under Section 409A (together, the “Deferred Compensation Separation Benefits”) will be paid or otherwise provided until Executive has a “separation from service’’ within the meaning of Section 409A.

 

 

(ii) Notwithstanding anything to the contrary in this Agreement, if Executive is a “specified employee’’ within the meaning of Section 409A at the time of Executive’s termination (other than due to death), then the Deferred Compensation Separation Benefits that are payable within the first six (6) months following Executive’s separation from service, will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive’s separation from service. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following Executive’s separation from service, but prior to the six (6) month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive’s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Agreement is intended to constitute separate payments for purposes of Section l.409A-2(b)(2) of the Treasury Regulations.

 

(iii) Any amount paid under this Agreement that satisfies the requirements of the “short-term deferral’’ rule set forth in Section l.409A-l(b)(4) of the Treasury Regulations will not constitute Deferred Compensation Separation Benefits for purposes of clause (i) above.

 

(iv) Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-l(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit (as defined below) will not constitute Deferred Compensation Separation Benefits for purposes of clause (i) above.

 

(v) The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A.

 

(d) Confidential Information Agreement. Executive’s receipt of any payments or benefits under Section 7 will be subject to Executive continuing to comply with the terms of Confidential Information Agreement (as defined above).

 

(e) No Duty to Mitigate. Executive will not be required to mitigate the amount of any payment contemplated by this Agreement, nor will any earnings that Executive may receive from any other source reduce any such payment.

 

 

9. Definitions.

 

(a) Benefit Plans. For purposes of this Agreement, “Benefit Plans” means plans, policies or arrangements that the Company sponsors (or participates in). A requirement that the Company provide Executive and Executive’s eligible dependents with coverage under the Benefit Plans will not be satisfied unless the coverage is no less favorable than that provided to senior executives of the Company at any applicable time during the period Executive is entitled to receive severance pursuant to Section 7(a). The Company may, at its option, satisfy any requirement that the Company provide coverage under any Benefit Plan by (i) reimbursing Executive’s premiums under Title X of the Consolidated Budget Reconciliation Act of 1985, as amended (“COBRA”) after Executive has properly elected continuation coverage under COBRA (in which case Executive will be solely responsible for electing such coverage for his eligible dependents), or (ii) providing coverage under a separate plan or plans providing coverage that is no less favorable or by paying Executive a lump-sum payment which is, on an after-tax basis, sufficient to provide Executive and Executive’s eligible dependents with equivalent coverage under a third party plan that is reasonably available to Executive and Executive’s eligible dependents.

 

(b) Cause. For purposes of this Agreement, “Cause” is defined as (i) a material act of dishonesty made by Executive in connection with Executive’s responsibilities as an employee of the Company, (ii) Executive’s conviction of, or plea of nolo contendere to, a felony or any crime involving fraud, embezzlement or any other act of moral turpitude, (iii) Executive’s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom Executive owes an obligation of nondisclosure as a result of Executive’s relationship with the Company, (iv) Executive’s willful breach of any obligations under this Agreement or the Confidential Information Agreement, or (v) Executive’s continued failure to perform his material employment duties after Executive has received a written demand of performance from the Company consistent with the terms of this Agreement which specifically sets forth the factual basis for the Company’s belief that Executive has not substantially performed his duties and has failed to cure such non-performance to the Company’s satisfaction within 90 calendar days after receiving such notice.

  

 

(c) Change in Control. For purposes of this Agreement, “Change in Control” of the Company is defined as:

 

(i) Change in Ownership of the Company. A change in the ownership of the Company which occurs on the date that any one person, or more than one person acting as a group (“Person”), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than 50% of the total voting power of the stock of the Company, except that any change in the ownership of the stock of the Company as a result of a private financing of the Company that is approved by the Board will not be considered a Change in Control; or

 

(ii) Change in Effective Control of the Company. If the Company has a class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), a change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purposes of this clause (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control; or

 

(iii) Change in Ownership of a Substantial Portion of the Company’s Assets. A change in the ownership of a substantial portion of the Company’s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions. For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.

 

For purposes of this Section 10(c), persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company.

 

Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if: (i) its sole purpose is to change the state of the Company’s incorporation, or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction.

 

 

(d) Code. For purposes of this Agreement, “Code” means the Internal Revenue Code of 1986, as amended.

 

(e) Good Reason. For purposes of this Agreement, “Good Reason” means Executive’s resignation within thirty (30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without Executive’s consent: (i) the material reduction of Executive’s authority, duties or responsibilities; (ii) a material reduction of Executive’s Base compensation; or (iii) the relocation of Executive to a facility or a location of fifty (50) miles or more from Executive’s then current office location. Executive’s resignation will not be deemed to be for Good Reason unless Executive has first provided the Company with written notice of the acts or omissions constituting the grounds for “Good Reason’’ within ninety (90) days of the initial existence of the grounds for “Good Reason” and a reasonable cure period of not less than thirty (30) days following the date the Company receives such notice, and such condition has not been cured during such period.

 

(f) Section 409A. For purposes of this Agreement, “Section 409A” means Section 409A of the Code and any formal regulations and guidance thereunder and any applicable state law equivalent, as each may be amended or promulgated from time to time.

 

(g) Section 409A Limit. For purposes of this Agreement, “Section 409A Limit” will mean the lesser of two (2) times: (i) Executive’s annualized compensation based upon the annual rate of pay paid to Executive during the Company’s taxable year preceding the Company’s taxable year of Executive’s termination of employment as determined under Treasury Regulation l.409A- l(b)(9)(iii)(A)(l) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which Executive’s employment is terminated.

 

10. Confidential Information. Executive shall continue to be bound by the Confidential Information Agreement during the term of his employment hereunder.

 

11. Assignment. This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal representatives of Executive upon Executive’s death, as applicable, and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, “successor’’ means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other attempted assignment, transfer, conveyance or other disposition of Executive’s right to compensation or other benefits will be null and void.

 

 

12. Notices. All notices, requests, demands and other communications called for hereunder will be in writing and will be deemed given (i) on the date of delivery if delivered personally, (ii) one (1) day after being sent by a well-established commercial overnight service, or (iii) four (4) days after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at the following addresses, or at such other addresses as the parties may later designate in writing:

 

If to Executive, at the last residential address known by the Company.

 

13. Severability. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision.

 

14. Integration. This Agreement, together with the Confidential Information Agreement represents the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements whether written or oral. This Agreement may be modified only by agreement of the parties by a written instrument executed by the parties that is designated as an amendment to this Agreement.

 

15. Waiver of Breach. The waiver of a breach of any term or provision of this Agreement, which must be in writing, will not operate as or be construed to be a waiver of any other previous or subsequent breach of this Agreement.

 

16. Headings. All captions and section headings used in this Agreement are for convenient reference only and do not form a part of this Agreement.

 

17. Tax Withholding. All payments made pursuant to this Agreement will be subject to withholding of applicable taxes.

 

18. Governing Law. This Agreement will be governed by the laws of the State of California (with the exception of its conflict of laws provisions).

 

19. Acknowledgment. Executive acknowledges that he has had the opportunity to discuss this matter with and obtain advice from his private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is knowingly and voluntarily entering into this Agreement.

 

20. Counterparts. This Agreement may be executed in counterparts, and each counterpart will have the same force and effect as an original and will constitute an effective, binding agreement on the part of each of the undersigned.

 

[Remainder of Page Intentionally Left Blank]

 

 

IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement as of the date set forth above.

 

TENON MEDICAL, INC.
By:
	Name:	▇▇▇▇▇▇ ▇▇▇▇▇▇
	Title:	CEO

 

EXECUTIVE:
Name:	▇▇▇▇ ▇▇▇▇▇▇

 

 

SCHEDULE A

 

Restricted Stock Vesting Schedule

 

1.

32,885 shares of the Original Restricted Stock shall vest on the one (1) year anniversary of the Vesting Commencement Date.

 

2.

65,756 shares of the Original Restricted Stock shall vest in four equal installments of 16,439, semi-annually over the next two (2) years.

 

3.

19,736 shares of the Original Restricted Stock shall vest on the 18-month anniversary of the Vesting Commencement Date if the Company has achieved cumulative Net Revenue of $8.0 million during such 18-month period..

 

4.

19,737 shares of the Original Restricted Stock shall vest on the 36-month anniversary of the Vesting Commencement Date if the Company has achieved cumulative Net Revenue of $20.0 million during such 36-month period.

 

Each date set forth above shall be deemed a “Vesting Date”, and the vesting of the Original Restricted Stock on any Vesting Date shall be subject to the Executive continuing to be engaged with the Company through each such date. Each Vesting Date pursuant to Paragraph 1 and 2 above shall be deemed a “Time Vesting Date” and each Vesting Date pursuant to Paragraph 3 and 4 shall be deemed an “Earnout Vesting Date”.

 

Additional Restricted Stock shall vest pro rata at the same rate and upon the same events as the Original Restricted Stock.